Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study..

N Engl J Med. 2005 Jul 7;353(1):33-45.

2.

When and how to treat essential thrombocythemia.

Barbui T, Finazzi G.

N Engl J Med. 2005 Jul 7;353(1):85-6. No abstract available.

PMID:
16000360
3.

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Samuelson B, Chai-Adisaksopha C, Garcia D.

J Thromb Thrombolysis. 2015 Nov;40(4):474-9. doi: 10.1007/s11239-015-1218-2. Review.

PMID:
25894476
4.

Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M.

Eur J Haematol. 2017 Feb;98(2):106-111. doi: 10.1111/ejh.12806. Epub 2016 Sep 19.

PMID:
27557754
5.

[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].

Iványi JL, Marton É, Plander M, Szendrei T.

Orv Hetil. 2016 Feb 28;157(9):336-41. doi: 10.1556/650.2016.30323. Hungarian.

PMID:
26895801
6.

Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.

Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E.

Acta Haematol. 2007;118(4):215-8. Epub 2007 Nov 29. No abstract available.

PMID:
18057866
7.

Anagrelide: what was new in 2004 and 2005?

Petrides PE.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. Review.

PMID:
16810615
8.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group..

Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.

9.

[Treatment of essential thrombocythemia].

Alvarez-Larrán A, Cervantes F, Besses C.

Med Clin (Barc). 2013 Sep 21;141(6):260-4. doi: 10.1016/j.medcli.2013.01.016. Epub 2013 Mar 13. Review. Spanish.

PMID:
23490491
10.

Anagrelide: a review of its use in the management of essential thrombocythaemia.

Wagstaff AJ, Keating GM.

Drugs. 2006;66(1):111-31. Review.

PMID:
16398570
11.
12.

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.

Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR.

J Clin Oncol. 2009 Jun 20;27(18):2991-9. doi: 10.1200/JCO.2008.20.3174. Epub 2009 Apr 13.

13.

Therapeutic options for essential thrombocythemia and polycythemia vera.

Solberg LA Jr.

Semin Oncol. 2002 Jun;29(3 Suppl 10):10-5. Review.

PMID:
12096352
14.

[Anagrelide in the treatment of thrombocythemia essential (ET)].

Mazur G, Wróbel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J, Kuliczkowski K.

Pol Arch Med Wewn. 2004 Dec;112(6):1445-50. Polish.

PMID:
15962609
15.

[Primary thrombocythemia: diagnosis and therapy].

Petrides PE.

Med Klin (Munich). 2006 Aug 15;101(8):624-34. Review. German.

PMID:
16896569
16.

Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.

Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:149-60. Review.

PMID:
8951786
17.

[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].

Ge X, Yang L, Jin J, Qian W, Li J, Yang R, Cao X, Jiang B, Wang Z, Hou M, Zhang W, Xiao Z, Zhao Y, Gao D, Zhang X, Wang S, Sun A, Fu J, Su L, Li K.

Zhonghua Xue Ye Xue Za Zhi. 2015 Jul;36(7):547-52. doi: 10.3760/cma.j.issn.0253-2727.2015.07.00. Chinese.

PMID:
26304075
18.

Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.

Mesquita Mdo C, Sol EB, Malarme M, Noubouossie D, Demulder AC.

Clin Ther. 2009 Nov;31(11):2559-64. doi: 10.1016/j.clinthera.2009.11.006.

PMID:
20110000
19.

Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.

Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM.

Thromb Res. 2015 May;135(5):846-51. doi: 10.1016/j.thromres.2015.02.023. Epub 2015 Feb 26.

PMID:
25743883
20.

Supplemental Content

Support Center